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Abstract: Glucocorticoid (GC) resistance is a crucial determinant of inferior response to chemotherapy
in pediatric acute lymphoblastic leukemia (ALL); however, molecular mechanisms underlying this
phenomenon are poorly understood. Deregulated splicing is a common feature of many cancers,
which impacts drug response and constitutes an attractive therapeutic target. Therefore, the aim of the
current study was to characterize global splicing profiles associated with GC resistance and determine
whether splicing modulation could serve as a novel therapeutic option for GC-resistant patients.
To this end, 38 primary ALL samples were profiled using RNA-seq-based differential splicing analysis.
The impact of splicing modulators was investigated in GC-resistant leukemia cell lines and primary
leukemic specimens. Our findings revealed, for the first time, markedly distinct splicing landscapes
in ALL samples of B-cell precursor (BCP)-ALL and T-ALL lineages. Differential splicing events
associated with GC resistance were involved in RNA processing, a direct response to GCs, survival
signaling, apoptosis, cell cycle regulation and energy metabolism. Furthermore, our analyses showed
that GC-resistant ALL cell lines and primary samples are sensitive to splicing modulation, alone
and in combination with GC. Together, these findings suggest that aberrant splicing is associated
with GC resistance and splicing modulators deserve further interest as a novel treatment option for
GC-resistant patients.
Cancers 2020, 12, 723; doi:10.3390/cancers12030723 www.mdpi.com/journal/cancers
Cancers 2020, 12, 723 2 of 27
Keywords: alternative splicing; glucocorticoid resistance; pediatric acute lymphoblastic leukemia;
RNA sequencing; SF3B modulators
1. Introduction
Improvements achieved over the years in the treatment of childhood acute lymphoblastic leukemia
(ALL) have resulted in five-year survival rates approaching or even exceeding 90% in some high-income
countries [1,2]. However, up to 20% of patients experience a relapse which is largely caused by therapy
resistance of leukemic cells and comes with a dismal prognosis. Therefore, further research on the
identification and molecular characterization of drug-resistant subsets of ALL is warranted [3–6].
ALL patients are treated with combination chemotherapy, including glucocorticoids (GCs), in
particular dexamethasone (Dex) and predniso(lo)ne (Pred), which are administered at induction
the phase together with vincristine, L-asparaginase and anthracyclines [2,7,8]. Importantly, in vitro
resistance of primary childhood ALL cells to Pred was shown to correlate with both diminished
short and long-term clinical response to chemotherapy [9,10]. Moreover, blasts isolated at relapse
displayed higher GC resistance as compared to leukemic cells at diagnosis, which further underscores
the importance of GCs in ALL treatment outcomes [11].
Mechanistically, GC resistance frequently arises from the impaired activity of the glucocorticoid
receptor (GR) caused by diminished gene expression, mutations and reduced ligand and/or DNA
binding capacity [8]. GC response is mediated by various signaling transduction pathways downstream
the GR, including MAPK or NFκB signaling [12–14], and is suppressed by increased levels of
anti-apoptotic proteins such as BCL2 and MCL1 [15–18]. Moreover, alterations in transcription factors
interacting with GR affect its ability to regulate the expression of target genes [8,18]. For instance, loss of
IKZF1 function via gene deletions and splicing alterations was shown to directly alter GC transcriptional
response and induce GC resistance in B-cell-precursor (BCP) ALL [19,20]. In a genome-wide effort
to identify the genetic basis of drug sensitivity in ALL, Holleman et al. [15] revealed global gene
expression patterns associated with resistance to the core chemotherapeutics in ALL treatment,
including Pred. Differentially expressed genes between GC-resistant and sensitive ALL samples
involved multiple cellular processes including carbohydrate metabolism, apoptosis and nucleic acid
metabolism. Although many studies demonstrated the association of differential gene expression
with drug resistance in ALL [15,21,22], alterations in global mRNA splicing profiles have never been
investigated in this context.
Deregulated splicing occurs in many cancers and plays an important role in hematological
malignancies. Mutations in splicing factors influence pathogenesis and drug resistance in
myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) and chronic lymphocytic leukemia
(CLL) [23–28]. In these entities, splicing factor mutations perturb global splicing profiles, thereby
creating vulnerability to drugs targeting the spliceosome and, in particular, the SF3B complex [29,30].
Beyond splicing factor mutations, Yang and collaborators recently demonstrated that high levels of
global aberrant splicing have a negative prognostic impact in MDS patients [31].
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Whereas spliceosome mutations were infrequent in ALL [32], BCP-ALL cells did display
global aberrant splicing when compared with non-malignant controls [33,34]. Interestingly, we
previously showed that aberrant splicing of folylpolyglutamate synthetase (FPGS), a key determinant
of methotrexate (MTX) efficacy, is associated with MTX resistance in childhood ALL [35,36]. Notably,
high levels of one particular aberration, i.e., FPGS intron 8 partial retention, were also associated with
increased resistance to GCs. This suggests that leukemic cells of GC-resistant patients carry a more
profound splicing dysregulation which could be exploited for therapeutic purposes.
Building on these data, the aim of the current study is to characterize the global alternative
splicing profiles associated with ex vivo GC resistance in childhood ALL. Specifically, we investigated
differential splicing profiles in 38 primary childhood ALL samples by using RNA sequencing [37].
Finally, we tested whether resistant cell lines and primary specimens can be sensitized to GC treatment
by using SF3B modulators.
2. Results
2.1. Differential Splicing Landscape Associated with GC Resistance in Pediatric ALL
In order to evaluate whether GC resistance is associated with specific splicing patterns in
childhood ALL, we used RNA sequencing to profile transcriptomes of specimens obtained from 36
newly diagnosed and two relapsed pediatric ALL patients (Figure 1A). This study cohort was well
characterized with respect to clinical features and ex vivo drug resistance, including Dex and Pred
(Supplemental Data S1). The patient specimens were classified either as GC-sensitive (N = 15) or
GC-resistant (N = 23) based on ex vivo Dex and Pred LC50 values according to the previously established
cut-offs of 0.01 µg/mL and 0.1 µg/mL, respectively [9] (Figure 1B). Furthermore, we determined the
immunophenotype and genetic profile of the samples, including mutations in GR and recurrent
genetic alterations associated with ALL [21,38] (Figure 1C), which allowed us to account for possible
confounders in the analysis.
The global differential splicing profiles of GC-sensitive and GC-resistant samples were determined
using the rMATS algorithm (Figure 2A). This software identifies sequencing reads which support a
certain splice event (e.g., the inclusion or skipping of a certain exon in a gene of interest) and calculates
the inclusion levels (or Percentage Spliced-In, Ψ). Ψ is computed as the proportion of reads supporting
the inclusion of the exon in question divided by the sum of reads supporting the inclusion and skipping
of this exon. Subsequently, it compares the average Ψ values of GC-sensitive specimens with that
of GC-resistant samples by computing the Inclusion Level Difference (∆Ψ) and the corresponding
p-value and false discovery rate (FDR) for each splice event [37]. We found, in total, 994 significant
differential splicing events (FDR < 0.05, Figure 2B and Supplemental Data S2) affecting 762 genes.
Hierarchical clustering (Figure 2C) and principal component analysis (Figure 2D) based onΨ (inclusion
level) values of the detected splicing events showed that the majority of GC-resistant and GC-sensitive
samples clustered together; however, five specimens from each group clustered in their opposing class.
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Figure 1. Overview of de novo pediatric acute lymphoblastic leukemia (ALL) patient cohort. (A) 
Schematic representation of study design. Primary childhood leukemia samples (from both 
peripheral blood and bone marrow) were collected at diagnosis and processed for white blood cell 
(WBC) isolation. Samples with blast populations >80% were tested for ex vivo cytotoxicity (MTT) 
assays and processed for RNA sequencing. (B) Ex vivo glucocorticoid (GC) sensitivity levels. Isolated 
blasts were treated with Dex (concentration range: 0.0002–6.1 µg/mL) and Pred (concentration range: 
0.007–260 µg/mL). After 96 h, the samples were measured by MTT assay and the median lethal 
concentration (LC50—the concentration of the drug that kills 50% of cells as compared to the control) 
Figure 1. Overview of de novo pediatric acute lymphoblastic leukemia (ALL) patient cohort. (A)
Schematic representation of study design. Primary childhood leukemia samples (from both peripheral
blood and bone marrow) were collected at diagnosis and processed for white blood cell (WBC) isolation.
Samples with blast populations >80% were tested for ex vivo cytotoxicity (MTT) assays and processed
for RNA sequencing. (B) Ex vivo glucocorticoid (GC) sensitivity levels. Isolated blasts were treated
with Dex (concentration range: 0.0002–6.1 µg/mL) and Pred (concentration range: 0.007–260 µg/mL).
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After 96 h, the samples were measured by MTT assay and the median lethal concentration (LC50—the
concentration of the drug that kills 50% of cells as compared to the control) and 95% confidence interval
(CI) was determined. GC sensitivity cut-off was set at 0.01 µg/mL for Dex and 0.1 µg/mL for Pred. (C)
Chromosomal and genetic alterations. The table contains data concerning ploidy, immunophenotype,
ETV6-RUNX1 translocations, NR3C1 (GR) mutations and detection of gains and losses of several
genes relevant for ALL pathogenesis and GC resistance through MLPA analysis. MLPA: multiplex
ligation-dependent probe amplification, IPT: immunophenotype, GR: glucocorticoid receptor.
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Figure 2. Global splicing profiles related to GC resistance in the total cohort of childhood ALL 
patients. The figure depicts the results of differential splicing analysis performed on 15 GC-sensitive 
versus 23 GC-resistant childhood ALL samples using the rMATS algorithm. (A) Schematic 
representation of alternative splicing event types as detected by rMATS. ES: exon skipping (dark blue 
exon can be excluded from the mRNA transcript); RI: retained intron (thick black line represents the 
intron that is included in the mRNA); A3SS: alternative 3’ splice site; A5SS: alternative 5’ splice site 
(depending on the position of the splice site, part of introns are included in the mRNA and depicted 
as striped boxes). (B) The number of significant splicing (FDR < 0.05) events per each type. (C) 
Hierarchical clustering performed using all significant differential splicing events. Inclusion levels (or 
Percentage Spliced-In, Ψ) per each event were generated by rMATS, Z-score-normalized and plotted 
as a heatmap. The colored bar over the heatmap represents the sensitivity to GCs (green—GC-
sensitive samples, brown—GC-resistant). (D) Principal component analysis (PCA) plot created by 
using Ψ values for all significant differential splicing events. 
2.2. BCP- and T-cell ALL Show Distinct Splicing Patterns 
Previous reports indicate that BCP-ALL harbored distinct gene expression signature compared 
to T-ALL [15], which was confirmed in the current dataset (Figure A1A and Supplemental Data S3). 
Since alternative splicing is known to demonstrate tissue-specificity [39,40], cell-type-specific 
Figure 2. Global splicing profiles related to GC resistance in the total cohort of childhood ALL patients.
The figure depicts the results of differential splicing analysis performed on 15 GC-sensitive versus
23 GC-resistant childhood ALL samples using the rMATS algorithm. (A) Schematic representation
of alternative splicing event types as detected by rMATS. ES: exon skipping (dark blue exon can be
excluded from the mRNA transcript); RI: retained intron (thick black line represents the intron that
is included in the mRNA); A3SS: alternative 3’ splice site; A5SS: alternative 5’ splice site (depending
on the position of the splice site, part of introns are included in the mRNA and depicted as striped
boxes). (B) The number of significant splicing (FDR < 0.05) events per each type. (C) Hierarchical
clustering performed using all significant differential splicing events. Inclusion levels (or Percentage
Spliced-In, Ψ) per each event were generated by rMATS, Z-score-normalized and plotted as a heatmap.
The colored bar over the heatmap represents the sensitivity to GCs (green—GC-sensitive samples,
brown—GC-resistant). (D) Principal component analysis (PCA) plot created by using Ψ values for all
significant differential splicing events.
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2.2. BCP- and T-Cell ALL Show Distinct Splicing Patterns
Previous reports indicate that BCP-ALL harbored distinct gene expression signature compared
to T-ALL [15], which was confirmed in the current dataset (Figure A1A and Supplemental Data
S3). Since alternative splicing is known to demonstrate tissue-specificity [39,40], cell-type-specific
differences could potentially affect our analysis. To address this issue, we examined whether the
differences between BCP-ALL and T-ALL were also reflected in splicing profiles. By comparing the
transcriptomes of six T-cell and 26 BCP (pre-B and common) ALL samples with rMATS, we found 2097
significant differential splicing events (Figure A1B,D) affecting 1416 genes.
Gene ontology (GO) analysis (Figure A1E) revealed that genes differentially spliced between BCP
and T-ALL are largely involved in the regulation of transcription and histone modifications, mRNA
processing as well as several signaling pathways. Not surprisingly, many differentially spliced genes
were involved in B- and T-cell differentiation processes (i.e., LCK, ICAM2, RUNX1), including T-cell
receptor signaling and MAPK cascade (i.e., FLT3, STAT5B and MAP kinases) (Supplemental Data S3).
Given that both subtypes of ALL show fundamental differences in their splicing profiles as well as in
previously reported mechanisms of resistance to GCs [19,41], we proceeded to analyze differential
splicing in relation to GC resistance within each subtype separately.
2.3. Differential Splicing in Relation to GC Resistance in BCP-ALL and T-ALL
Differential splicing analysis performed on 10 GC-sensitive and 16 GC-resistant BCP-ALL samples
uncovered 1035 significant events affecting 777 genes and resulting in a better separation of the two
groups compared to the total cohort (Figure 3A,B). The majority of splicing events in the BCP-ALL had
∆Ψ ranging between –0.05 and 0.05, indicating overall small differences between GC-resistant and
GC-sensitive samples (Supplemental Data S4). The comparison between two GC-sensitive and four
GC-resistant T-ALL samples revealed a total of 932 significant differential splicing events occurring in
722 genes (Figure 3A,B and Supplemental Data S5).
Our unbiased GO analysis revealed that some processes are commonly affected in both BCP-ALL
and T-ALL (Figure 3C,E). This includes for instance factors involved in RNA metabolism, in particular
regulation of transcription (histone modifications) and mRNA splicing (i.e., U2AF1, multiple HNRNPs
and DDX helicases). Interestingly, perturbation of some members of this commonly affected pathway
was subtype-specific, as SRSF3 and SRPK2 were found alternatively spliced in the T-ALL dataset only,
while SRSF5 and SRSF7 were specific for the BCP-ALL group. Furthermore, many processes directly
linked to GC-induced responses were affected in a subtype-specific manner.
Interestingly, alternative splicing in BCP-ALL also affected multiple genes encoding proteasomal
subunits which regulate important B-cell functions, including antigen presentation, NFkB and Wnt
signaling pathways. Furthermore, this dataset was enriched in genes regulating apoptosis and cell
cycle (Figure 3D) which can influence GC resistance. In particular, the pro-apoptotic factor BAX was
affected by increased exon skipping (ES) in GC-resistant samples. TP53 isoform γ (exon 9γ inclusion)
appeared more expressed in sensitive samples, while TP53 isoform β (exon 9β inclusion) showed
higher expression in resistant samples.
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(ES exon s i t retention, A3 S—alternative 3’ splice site, A5SS—alternative 5’ splice
site). (B) Hierarchical clustering performed using all significant differential splicing events. Inclusion
levels (or Percentage Spliced-In, Ψ) per each event were generated by rMATS, Z-score-normalized
and plotted as a heatmap. The colored bar over the heatmap represents the sensitivity to GCs
(green—GC-sensitive samples, brown—GC-resistant). (C,E) Top 20 major gene ontology (GO) terms
with the largest numbers of genes in the BCP-ALL and T-ALL datasets respectively. GO search was
performed in gProfiler by selecting GO, KEGG and REACTOME databases and ClueGO (Cytoscape
plugin) using all genes affected by significant differential splicing events. (D,F) Gene network
analysis of differentially spliced genes in relation to GC resistance in BCP-ALL and T-ALL respectively.
Two representative gene networks per each dataset are shown (“regulation of apoptosis” and “regulation
of cell cycle” for the BCP-ALL, “cellular stress” and “oxidative phosphorylation” for the T-ALL).
Gene networks were obtained using the STRING tool and visualized in Cytoscape. The color represents
the Ψ and the size of the nodes represents degree (number of connection to neighboring nodes).
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Superoxide dismutases (SOD1, cytoplasmic and SOD2, mitochondrial) encode antioxidant
enzymes that degrade harmful superoxide radicals in the cell. Both SOD1 and SOD2 showed an
increase in exon inclusion in GC-resistant samples. Furthermore, differential splicing affected two
genes directly linked to GR signaling: HSP90AA1, GR-associated molecular chaperone, and SGK1,
serum/glucocorticoid regulated kinase 1. The latter plays an important role in cellular responses to
stress and exerts anti-apoptotic functions [18]. In addition, we identified a group of genes involved in
focal adhesion and cytoskeleton organization which holds importance for cell-stroma interaction and
the acquisition of stem-like properties (i.e., VIM, CD44, ITGA4/5).
Multiple genes involved in energy metabolism were differentially spliced uniquely in the context
of GC resistance in T-ALL (Figure 3E,F). This included regulatory glycolytic enzymes (PFKL and
PFKM), core members of the ubiquinol-cytochrome c reductase (UQCRC1 and UQCRC2) as well as
five crucial subunits of the NADH dehydrogenase (NDUF, Figure 3F). These components of energy
metabolism were affected by RI events elevated in GC-resistant samples, as well as alternative 3’ or 5’
splice site selection (ASS3 and ASS5).
In addition, a more targeted search within the T-ALL subtype revealed differentially spliced
genes involved in several signaling pathways crucial to cell survival (Figure 3F). This included BAX
(affected by increased RI in GC-resistant samples), members of the NFκB (i.e., CHUK showing increased
inclusion of exon 7 in GC-resistant samples and IKBKB with a minor A5SS event) and MAPK signaling
(i.e., MAP2K2 showing a very minor RI and MAP3K8 displaying ES in GC-resistant samples).
Finally, we evaluated whether splicing perturbations of genes involved in pathways relevant for GC
resistance directly affected sequences coding for structural and/or functional domains (Figure A2A,D,
Supplemental Data S6). This was indeed observed for apoptosis and cell cycle regulators in BCP-ALL
and suggests that these events can have a negative impact on protein function. In contrast, many
factors involved in energy metabolism and signaling in T-ALL were not directly affected by splicing
aberrations within specific protein domains.
2.4. Validation of Selected Differential Splicing Events
To validate the results of differential splicing analysis, we carried out semi-quantitative RT-PCR to
confirm 13 splice events in BCP-ALL and 19 splice events in T-ALL, in which was found a significant
differential between GC-resistant and GC-sensitive samples by rMATS (Figure 4). The PCR-based
ratios were calculated analogously to the Ψ values. The correlation between rMATS and RT-PCR
results varied for different genes, partly because ∆Ψ values were often relatively small between the two
groups, despite being significant. However, there was a moderate to a strong statistically significant
correlation between the rMATS-generated data and RT-PCR. For all 13 genes in BCP-ALL: R2 = 0.602,
p < 0.01. For all 19 genes in T-ALL: R2 = 0.4717, p < 0.01 (Figure A3).
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Figure 4. PCR validations of differential splicing events predicted by the rMATS algorithm. The PCR
validations were performed for 13 differential splicing events identified in BCP-ALL and 19 differential
splicing events identified in T-ALL (Figure A1). The figure depicts 3 selected genes per each subtype,
including splicing regulators and GC resistance-related genes. (A) Ψ values generated by rMATS in
GC-resistant and GC-sensitive samples (FDR < 0.05). (B) Electrophoresis gels illustrating the results of
PCR validations for selected differential splicing events identified by rMATS. (C) Association between
rMATS-calculated and PCR-derived Ψ values (PCR ratio) was evaluated per each validated event
using the linear regression model. Ex: exon inclusion; ∆Ex: exon skipping; Int: retained intron; ∆Int:
intron exclusion.
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2.5. Splicing Modulation Potently Inhibits Growth of Dex-Resistant ALL Cells and Co-Operates with Dex to
Eradicate T-ALL Cells
To evaluate the therapeutic potential of splicing modulation in drug-resistant ALL, we first determined
the response to pladienolide B (Plad-B) in a T-ALL cell line CCRF-CEM-WT and three Dex-resistant
CEM sublines: CEM/R30dm (unknown mechanism of Dex resistance), CEM-R5 and CEM-R5C3 (both
characterized by defective GR function). Remarkably, all cell lines responded to comparably low nanomolar
concentrations of Plad-B (Figure 5A). This growth inhibition was associated with dose and time-dependent
cell cycle arrest (Figure 5B,C). RNA sequencing performed on CEM-WT and CEM/R30dm cells treated
with 4nM Plad-B for 6 h revealed wide-spread changes in splicing (Figure 5D).Cancers 2020, 12, x FOR PEER REVIEW 11 of 27 
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GC-resistant sublines: CEM-R30dm, CEM-R5 and CEM-R5C3 in a 72 h MTT assay. The plot depicts the
mean ± SD of at least 3 independent experiments. (B,C) Time-dependent inhibition of proliferation
(B) and cell cycle arrest (C) induced by treatment with 4 nM Plad-B in CEM-WT and CEM-R30dm.
The panel depicts the mean ± SD of 2 independent experiments. T-test was used for (B); asterisks in
(B,C) indicate statistical significance (p < 0.05); in (B), statistical significance for CEM-WT is indicated
above the plotted line and for CEM-R30dm below the plotted line. Chi-square test was used for (C).
(D) Hierarchical clustering of significant differential splicing events between untreated (NT) and 4
nM Plad-B-treated CEM-WT and CEM-R30dm cells. Inclusion levels (Ψ) were generated by rMATS
Z-score-normalized and plotted as a heatmap. (E) The effect of MAMB and Plad-B treatment on primary
samples of childhood ALL patients and non-malignant cells. The first two graphs depict LC50 values
(the concentration of the drug that kills 50% of cells as compared to the control) obtained for primary
ALL samples and non-malignant bone marrow specimens in the 96 h MTT assay. (F) Percentage of
viable cells in 3 cell subpopulations of primary childhood T-ALL samples (blast cells, mature T-cells and
B-cells) upon a 72 h incubation with 10 nM Plad-B. The p-value was calculated using the Mann–Whitey
U test. (G) Percentage of viable cells in 3 cell subpopulations of primary childhood T-ALL samples
(blast cells, mature T-cells and B-cells) upon a 72 h incubation with Plad-B alone, Dex alone or the
combination of the two. Each graph represents a single sample. The concentrations of Plad-B and Dex
that were equivalent to the single drug LC50 values as determined in the 96 h MTT assay were used
(with the exception of sample T-ALL4 for which not enough material was available to perform the MTT
assay prior to flow cytometry. For this sample, the drug concentrations were selected based on the
mean LC50 values in the total number of T-ALL samples assessed).
To further validate these results, we tested the sensitivity to the splicing modulators Meayamycin
B (MAMB) and Plad-B in primary cells of 17 childhood ALL samples and 11 non-malignant bone
marrow controls using MTT assay. Notably, primary ALL samples showed a remarkable sensitivity to
both agents (Figure 5E) and the LC50 values in ALL cells tended to be lower compared to non-malignant
samples (P = 0.07, median LC50 values 0.42 ± 0.05 nM and 0.57 ± 0.1 nM, respectively, for MAMB and
P = 0.04, mean LC50 values 9.9 ± 2.1 nM and 18.7 ± 3.2 nM, respectively, for Plad-B).
To gain further insight into the potential therapeutic window of these compounds, we exposed 7
T-ALL samples to Plad-B for 72 h, followed by flow cytometry-based immunophenotyping (Figure 5F).
We observed that, although in two samples, mature CD5+ T-cells were less affected as compared to blast
cells (also see Figure 5G), overall, both the blasts and mature T-cells were affected to a similar extent.
In contrast, CD19+ B-cells were significantly less affected than T-lineage cells (P = 0.04, Figure 5F).
Next, we tested whether Plad-B combined with Dex is more selective towards leukemic cells
as compared to Plad-B alone. For this analysis, we selected T-ALL samples characterized by mild
to high Dex resistance. To this end, we treated five samples of T-ALL patients for 72 h with the
combination of Plad-B and Dex, as well as each of the drugs alone. In four cases, we observed that
leukemic blasts were more efficiently eradicated by the combination as compared to both single drugs
(Figure 5G). Interestingly, leukemic blasts were affected by the combination to a larger extent when
compared to mature lymphocytes (CD5+ T-cells and CD19+ B-cells); however, there was some variation
between patients.
Finally, we assessed the combination of 1 nM Plad-B with a range of Dex concentrations in our
Dex-resistant CEM cell line models. While in CEM-R5 and CEM-R5C3 the two agents showed slightly
antagonistic interaction (not shown), in CEM/R30dm the combination was highly synergistic (mean
CI = 0.276 ± 0.055, Figure A4). This suggests that patients with non-GR-related Dex resistance could
potentially benefit from this drug combination.
3. Discussion
To our knowledge, this is the first study to show the association between ex vivo GC resistance
and altered splicing profiles in pediatric BCP- and T-ALL. The detection of differential splicing in
primary samples could potentially be affected by large intra-patient heterogeneity of clinical and
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genetic features. The patient groups compared in our study were homogeneous, except for CDKN2A/B,
BTG1 and EBF1 alterations which appeared more frequently among GC-resistant samples. However,
we did not observe distinctive splicing profiles associated with any of these genetic aberrations.
We report that differences between BCP- and T-ALL cells at the gene expression level are also
extended to alternative splicing. Many of the differentially spliced genes between BCP and T-ALL
were involved in processes related to normal biological/immune function of both subtypes (i.e.,
B-cell and T-cell differentiation including T-cell receptor and MAPK signaling) and, therefore, likely
reflect lineage-specific functional differences [42,43]. It was previously reported that many genes are
alternatively spliced in the context of normal immunological functions of healthy T-cells, including
specific pathways being regulated by splicing upon activation [40,44]. This data illustrates that it is
crucial to investigate GC resistance in a lineage-specific context.
We found several pathways perturbed by differential splicing in BCP and T-ALL in relation to
GC resistance. Selected splicing events, even though characterized by low ∆Ψ values, were validated
by RT-PCR and showed moderate to strong correlation to rMATS-derived Ψ values in the majority
of cases. However, due to the semiquantitative nature of the RT-PCR method, our results should be
additionally confirmed by qRT–PCR in future studies. In our dataset, several differentially spliced
genes were involved in RNA processing and splicing regulation. Some of these splice factor genes
were common to both ALL subtypes (i.e., U2AF1 and HNRNPA1) while others were specific to
BCP-ALL (i.e., HNRNPA2B1, HNRNPK and HNRNPM, SRSF5 and SRSF7) or T-ALL (SRSF3 and
SRPK2). Such proteins are known to auto-regulate their own splicing [45] and are likely to influence
global splicing profiles and thereby affect cancer pathogenesis and progression. For instance, in the
context of BCP-ALL, Black and collaborators [33] reported altered splicing of several cancer driver
genes to be more common compared to somatic mutations. Moreover, they report that differential
splicing of HNRNPA1 - whose expression levels are altered in several cancer types - leads to transcript
degradation. The differences found between ALL subtypes highlighted in our data could reflect the
tissue-specificity of splicing regulation. In particular, we want to emphasize that specific classes of
splicing regulators are associated with specific immunophenotypes. Hence, distinct regulatory splicing
pathways/networks related to GC resistance should be investigated within each subtype, to avoid
interference of different splicing-related to processes such as cell differentiation. Future studies should
evaluate to which degree differential splicing of these particular splicing factors contributes to the
globally altered splicing profiles in GC-resistant cells.
Leivonen et al. [46] showed that alternative splicing profiles of high-risk diffuse large B-cell
lymphoma (DLBCL) patients are associated with survival, distinguish DLBCL molecular subtypes
and influence genes involved in drug resistance. Extending these observations to ALL, we showed
that multiple genes relevant for GC response are alternatively spliced in primary childhood ALL
cells, potentially contributing to diminished susceptibility to GCs. Firstly, we found splice alterations
of HSP90AA1 and SGK1, both involved in GR signaling, suggesting that aberrant splicing could
indirectly affect proper GR function. Secondly, many genes involved in signaling pathways, cell
cycle regulation and apoptosis (known mediators of GC signaling) were differentially spliced in the
context of GC resistance. This is in agreement with previous reports showing that primary ALL cells
which are in vitro resistant to GCs display defects occurring downstream of nuclear translocation of
the GR [47,48]. For instance, TP53 spliced variants β and γ have previously been reported to alter
the transcriptional activity of TP53α consequently affecting cell cycle and apoptosis regulation [49].
Although functional differences between TP53β and TP53γ remain unclear, they could presumably
interfere with GC-related anti-proliferative and pro-apoptotic effects. GC-induced apoptosis was
also reported to be antagonized by increased signaling via kinase networks, including the MAPK
pathway [12,13,18]. In this study, we found GC resistance-related aberrant splicing of the pro-apoptotic
protein BAX as well as genes involved in multiple signaling pathways (i.e., NFκB, MAPK, PI3K/AKT
and JNK signaling). For instance, elevated exon 7 inclusion of CHUK found in GC-resistant T-ALL
samples could potentially lead to increased activity of this NFκB activator and consequently increased
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cell survival. Similarly, differential splicing of genes coding for subunits of the proteasome, an
important regulator of NFκB signaling, might contribute to GC resistance in BCP-ALL. In line with
this hypothesis, primary Dex-resistant ALL specimens were previously shown to display sensitivity to
proteasome inhibitors, which in low concentrations were able to sensitize these samples to Dex [50].
Interestingly, genes involved in energy metabolism were differentially spliced, particularly
in T-ALL. GCs induce a metabolic shift from glycolysis towards oxidative phosphorylation and
it is postulated that oxidative stress plays a central role in GC-induced apoptosis of leukemic
cells [12,51]. We found that GC-resistant T-ALL cells display altered splicing (in particular intron
retention) of multiple genes involved in oxidative phosphorylation, in particular components of
ubiquinol-cytochrome c reductase and NADH dehydrogenase complex (which promotes DNA
damage-induced apoptosis through the production of reactive oxygen species (ROS)) [51]. As intron
retention often results in premature stop codons and transcript degradation, these changes are likely to
result in diminished GC-induced oxidative phosphorylation and, therefore, suppress the production of
ROS and consequently apoptosis induction. Similarly, we found increased inclusion of specific exons in
SOD1 and SOD2 genes in resistant BCP-ALL samples. GC treatment was shown to downregulate SOD1
which renders cells more vulnerable to ROS [18]. It is conceivable that GC-resistant BCP-ALL cells
are less prone to GC-induced ROS-mediated apoptosis due to an increased level of SOD1. However
intriguing, these hypotheses warrant functional validation. Many of the detected splicing events
directly affect sequences coding for structural and/or functional protein domains and, therefore,
are likely to result in loss of protein function. The impact of alterations that do not directly affect
protein domains is more challenging to predict; however, intron retentions are likely to introduce
premature termination codons resulting in transcript degradation or truncated dysfunctional proteins.
Furthermore, evaluation of the clinical and prognostic relevance of the splicing alterations uncovered
in this study was hampered by insufficient sample numbers to be able to perform survival analysis.
Low sample numbers (in particular for T-ALL) are a limitation of the current study and, therefore,
our findings should be further confirmed in larger datasets. Subsequent studies should focus on
determining the fate and functionality of GC-related splice variants, followed by mechanistic studies
and evaluation of the clinical relevance.
Finally, we demonstrated that splicing modulators are highly effective against (GC-resistant) ALL
cells. Our data extend a previous report showing that MAMB was able to eradicate multidrug-resistant
breast cancer cells [52] and provide an attractive pharmacological opportunity for chemo-refractory
patients. Furthermore, our results suggest that combining splicing modulation with GCs might elicit
a favorable effect in T-ALL patients with functional GR; however, the response showed variation
between individuals. Possible reasons for these differences include technical issues (differences in
viability of untreated cells between samples during the course of the experiment) as well as genetic
differences. For instance, it has previously been reported that cells with increased MYC/MYCN
expression are more vulnerable to splicing modulation [53–55]. In the current study, we assessed
spliceosome modulation in a very small pilot sample set, which limits the conclusions that can be drawn
regarding the intra-individual differences in response to Plad-B. Future investigations should extend
the current findings by focusing on specific subtypes of ALL to determine whether any specific genomic
or transcriptomic background renders ALL cells particularly sensitive to this novel therapeutic strategy.
Regarding potential toxic effects of Plad-B on non-malignant cells, we observed that in primary
T-ALL samples Plad-B affects mature T-cells to a similar extent as blast cells, whereas B-cells remained
largely unaffected. However, considering that mature T-cells in these patients are of the same lineage
as leukemic blasts, they might not completely reflect healthy cells. The notion that the combination
of Plad-B with Dex had more selective effects on blast cells as compared to mature lymphocytes
further encourages confirmatory studies in larger sample sets and with different classes of spliceosome
modulators. Given the variable potency of such compounds, future tests in combination with GCs
should be carried out to determine an optimal therapeutic window.
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4. Materials and Methods
4.1. Primary Childhood ALL Patient Samples and Leukemic Cell Lines
Thirty-six cryopreserved mononuclear bone marrow (BM) or peripheral blood (PB) cells from
pediatric ALL patients at diagnosis and 2 at relapse were included in this study. Patients were treated
according to the Dutch Childhood Oncology Group (DCOG) protocols ALL6–ALL9 [56] or German
Co-operative ALL (Co-ALL) protocols 92–97 [3]. All patients included in the study provided written
informed consent. The studies have been approved by the local medical ethical committee. Information
about the patient’s karyotype, immunophenotype and ploidy were provided by DCOG.
Samples with leukemic blast content >80% were selected for MTT-based drug cytotoxicity
screening, as previously described [57], and processed for RNA sequencing. Genetic alterations for
IKZF1, BTG1, EBF1, PAX5, CDKN2A/B, JAK2, PAR1 and RB1 were determined through MLPA analysis
as previously described [58]. The pediatric non-malignant controls were derived from 1 PB and 3
BM specimens of patients with cardiological disease and 2 specimens taken from 2 T-ALL patients in
remission (<5% blasts).
The human T-ALL cell line CCRF-CEM was obtained from ATCC. Dex-resistant CEM sublines used
in this study included: FPGS-deficient MTX-resistant, GC-cross-resistant subline CEM/MTX-R30dm
(kindly provided by Prof. J. McGuire [59]) and CEM-R5 (carrying a hemi or heterozygous L753F
mutation in the GR) and CEM-R5C3 (characterized by impaired induction of GR expression upon
Dex treatment), kindly provided by Prof. R. Kofler [60,61]. Cell lines were maintained in RPMI-1640
medium (Gibco) supplemented with 10% fetal calf serum (Greiner Bio-One) and 100 units/mL penicillin
G, and 100 µg/mL streptomycin sulfate (Gibco). Cultures were refreshed twice weekly.
4.2. Exposure to Spliceosome Modulators
Meayamycin B (MAMB) was kindly provided by Prof. K. Koide (Department of Chemistry,
University of Pittsburgh, USA), while pladienolide B (Plad-B) was purchased from Cayman Chemical
Company (Ann Arbor, USA). Dex was purchased from Centrafarm (Etten-Leur, The Netherlands).
Exponentially growing cell lines were seeded at a density of 0.1 × 106 cells/mL and exposed to Plad-B
for 72 h. Cryopreserved primary ALL samples were thawed and seeded at a density of 2 × 106
cells/mL [62] and exposed to Plad-B, Dex or the combination of both. Flow cytometry-based apoptosis
assay combined with immunophenotyping was performed after 72 h drug incubation. For cell lines,
the drug treatment was followed by RNA extraction (after 6 h incubation), flow cytometry-based
apoptosis assay, proliferation assay and cell cycle analysis assay.
4.3. RNA Isolation and Reverse Transcription
Total RNA was extracted from primary ALL patient samples and cell lines (exposed or unexposed
to Plad-B) using the RNeasy mini kit (Qiagen). For PCR analysis reverse transcription was carried out
using 1 µg RNA and M-MLV reverse transcriptase (Invitrogen) in a reaction buffer containing random
hexamer primers, dNTPs (Roche), and a ribonuclease inhibitor RNAsin (Promega).
4.4. RNA Sequencing
RNA integrity of isolated total RNA was assessed with RNA 6000 Nano Kit on a 2100 Bioanalyzer
system (Agilent Technologies). Sequencing libraries were prepared with the Illumina TruSeq Stranded
mRNA Library Prep LT Kit (RS-122-2201) and Agencount AMPure XP beads (Beckman Coulter). cDNA
library size and concentration were measured by Bioanalyzer.
Single-end, 100 bp-reads were obtained from HT-v4-SR100 Chip (8 lanes) on Illumina HiSeq
2500 System. The sequencing reaction yielded 22.3 ± 5.1 (average ± SD) million passing-filter raw
reads/sample (raw data are deposited in the GEO database with accession number: GSE133499).
The bioinformatic pipeline for data analysis was described previously [37] and summarized in the
Supplemental Methods.
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4.5. PCR Analysis of Splicing Events
Semi-quantitative PCR validation of selected candidate splicing events detected by rMATS was
performed by using primers listed in Table A3. PCR was carried out with 2×ReddyMix PCR master mix
(Thermo Fisher Scientific) [63] and the PCR products were resolved on 2% agarose gels with ethidium
bromide. Digital images of gels were processed with ImageJ Software (U.S. National Institutes of
Health) to calculate the intensity of each band. PCR ratio is calculated with the formula:
WT/(WT + ES) (1)
4.6. Flow Cytometry-Based Analyses
For the proliferation and apoptosis assay, cells were first stained with 7-AAD (Via-ProbeTM,
BD Bioscience). Subsequently, for assessment of apoptosis induction, 7-AAD-stained cells were
further labeled with FITC-conjugated Annexin-V antibody (ApoptestTM, VPS Diagnostic) in the
Annexin binding buffer (Ref. v13246, Thermo Fisher Scientific). For proliferation assay total
count of 7-AAD-negative cells was determined by using Flow-CountTM Fluorospheres (ref.7547053,
Beckman Coulter).
For cell cycle analysis the cells were permeabilized in 70% ethanol, followed by 30 min incubation
with RNAse A (100 µg/mL, Qiagen) and subsequent staining with propidium iodide (Thermo
Fisher Scientific).
In all assays, fluorescence was measured using BD FACS Canto II and Celesta flow cytometers
(BD Bioscience). Analysis was performed using BD FACS Diva software version 8.0.1.1. Details of the
flow cytometry analysis performed on primary samples are described in Supplemental Methods.
4.7. MTT Growth Inhibition and Cytotoxicity Assay
Growth inhibitory effects of MAMB/Plad-B in ALL cell lines, as well as primary ALL samples, were
determined after a continuous exposure using the colorimetric MTT dye reduction assay as described
previously [62,64]. ALL cell lines were incubated for 72 h, while primary ALL and non-malignant
samples for 96 h. In combination experiments, a fixed concentration of Plad-B was combined with a
dilution range of Dex. Fractional effect analysis was performed using the CalcuSyn software (Version
1.1.1, 1996, Biosoft), as described previously [65,66].
5. Conclusions
In conclusion, we demonstrated that BCP-ALL and T-ALL cells have distinct splicing landscape
and GC resistance was associated with lineage-specific differential splicing events. Global splicing
alterations affected GC resistance-relevant processes, including survival signaling, energy metabolism
and ROS-induced stress response. Finally, we show that targeting splicing with small molecule splicing
modulators constitutes an attractive treatment strategy that can potentially sensitize intrinsically more
GC-resistant T-ALL to treatment regimens including GC.
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Abbreviations
ALL acute lymphoblastic leukemia
GC: glucocorticoid
Dex dexamethasone
Pred predniso(lo)ne
BCP-ALL B-cell-precursor ALL
MDS myelodysplastic syndromes
AML acute myeloid leukemia
DLBCL large B-cell lymphoma
CLL chronic lymphocytic leukemia
FPGS folylpolyglutamate synthetase
MTX methotrexate
BM bone marrow
PB peripheral blood
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
MAMB Meayamycin B
WT wild type
Plad-B pladienolide B
DNA deoxyribonucleic acid
RNA ribonucleic acid
PCR polymerase chain reaction
M-MLV moloney murine leukemia virus
dNTPs nucleoside triphosphates
GEO gene expression omnibus
7-AAD 7-Aminoactinomycin D
FACS fluorescence activated cell sorting
rMATS replicate multivariate analysis of transcript splicing
ES exon skipping
RI retained intron
A3SS alternative 3’ splice site
A5SS alternative 5’ splice site
PCA principal component analysis
GO gene ontology
ROS reactive oxygen species
NR3C1 nuclear receptor 3C1
LCK lymphocyte specific protein tyrosine kinase
ICAM2 intercellular adhesion molecule 2
RUNX1 runt related transcription factor 1
FLT3 fms related tyrosine kinase 3
STAT5B signal transducer and activator of transcription 5B
VIM vimentin
CD44 cluster of differentiation 44
ITGA4 integrin subunit alpha
U2AF1 U2 small nuclear RNA auxiliary factor 1
HNRNP heterogeneous nuclear ribonucleoproteins
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DDX DEAD-box helicase
SRSF serine/arginine-rich splicing factor
SRPK2 SRSF protein kinase 2
PFKL phosphofructokinases
HSP90AA1 heat shock protein 90 alpha family class A member 1
CHUK component of inhibitor of nuclear factor kappa B kinase complex
IKBKB inhibitor of nuclear factor kappa B kinase subunit beta
Appendix A. Supplemental Methods
Appendix A.1. Detection of Alternative Splicing (AS) Events from RNA-Seq Data
rMATS version 3.2.5 was used to detect unique AS splicing events (ES, A5SS, A3SS and RI, with the exception
of mutually exclusive exons) with FDR < 0.05, which were imported to Microsoft Excel. Z-score calculation,
hierarchical clustering (agglomerative approach was applied using the hclust algorithm with Euclidean distance
and complete linkage methods) and principal component analysis (PCA) of were performed by using inclusion
levels (or Percentage Spliced In, Ψ) of AS events and visualized using ggplot2 [67] and ComplexHeatmap packages
(version 2.2.0) [68] in R (versions 3.5.3 and 3.6.2). The analysis of protein domains affected by splicing events
was performed with the Maser package (version 1.0.0) [69] in R (versions 3.5.3) upon conversion of the genomic
coordinates from hg19 to hg38 assembly (using AnnotationHub v. 2.14.5, GenomicRanges v. 1.34.0 and rtracklayer
v. 1.42.2 packages in R) [70–72].
Gene expression estimates were calculated with EdgeR and the correlation matrix (Figure A3) was visualized
by using ggplot2. For gene ontology (GO) analysis, gene IDs for significant differential splicing events were
uploaded into the STRING tool (v10.5) to retrieve interactions [73]. STRING interaction networks were imported
and annotated in Cytoscape (v3.6.1) [74]. Gene ontology analysis was performed within Cytoscape using the
ClueGO plugin [75]. In addition, gProfiler version r1741_e90_eg37 (https://biit.cs.ut.ee/gprofiler/gost) [76] was
used for pathway analysis of genes affected by AS and selecting GO, KEGG and REACTOME databases.
Appendix A.2. Flow Cytometry Analyses of Primary Samples
Primary samples showing more than 70% of apoptotic cells (Annexin-V-positive) in the control wells after 24 h
of incubation were excluded from further analysis. After 72 h of drug incubation cells were split into two fractions.
The first was used in a proliferation assay to measure absolute cell counts using Flow-CountTM Fluorospheres
(Beckman Coulter, USA). The second fraction was used for antibody staining combined with Annexin-V staining
(ApoptestTM, VPS Diagnostic, Netherlands). For this, the cells were stained with antibodies against B- and T-cell
surface markers (Supplementary Tables A1 and A2, below) and 7-AAD (Via-ProbeTM, BD Bioscience, USA).
Subsequently, the cells were washed and stained with Annexin-V as described above. Percentages of specific cell
subpopulation were calculated among Annexin-V-negative cells to ensure only the analysis of truly viable cells.
These percentages were next used to calculate cell counts in each subpopulation based on the absolute counts
obtained in the proliferation assay, according to the calculation shown below.
N of B-lymphocytes = (% B-lymphocytes in Annexin-V-neg population/100) ×
((% Total Annexin-V-negative cells/100) × absolute cell count) (2)
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of cells (all T-ALL samples were compared to all BCP-ALL samples). (A) Gene expression signature 
discriminates between BCP and T-ALL (Spearman correlation of gene expression estimates per each 
sample calculated with EdgeR). (B) The number of significant (FDR < 0.05) events per each type (ES—
exon skipping, RI—intron retention, A3SS—alternative 3’ splice site, A5SS—alternative 5’ splice site). 
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Figure A1. Distinct splicing profiles characterize childhood precursor BCP-ALL and T-ALL. The figure
depicts th gene expression profiles and differential splicing analysis comparing 6 T-ALL to 26 BCP-ALL
samples. This analysis was performed to evaluate differences n spli ing due to the lineage of c lls (all
T-ALL samples were compared to all BCP-ALL samples). (A) Gen expressio signature di criminates
between BCP and T-ALL (Spe rman correlation of gene expressi n estimates per each sample calculated
with EdgeR). (B) The numb r of significant (FDR < 0.05) events per each type (ES—exon skipping,
RI—i tron retention, A3SS—alternative 3’ splic site, A5SS—alternative 5’ splice site). (C) H erarchical
clustering performed usi g all significant differential splicing vents. In lusion levels (or Percentage
Spliced-In, Ψ) per each event were generated by rMATS, Z-score-normalized and plotted s a heatmap.
The colored bar over the heatmap represents the subtype of ALL (yellow—BCP-ALL, blue—T-ALL).
(D) PCA plot created by using Ψ values for all significant differential splicing events. (E) Top 20 major
GO terms with the largest numbers of genes in the dataset. GO search was performed in ClueGO
(Cytoscape plugin) using all genes affected by significant differential splicing events.
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Figure A2. Many splicing events relevant for GC resistance in BCP-ALL and T-ALL directly affect 
sequences coding for protein domains. The figure depicts heatmaps based on Ψ values visualized for 
Figure A2. Many splicing events relevant for GC resistance in BCP-ALL and T-ALL directly affect
sequences coding for protein domains. The figure depicts heatmaps based on Ψ values visualized for
clusters relevant for GC resistance in BCP-ALL ((A) apoptosis regulation, (B) cell cycle regulation) and
T-ALL ((C) energy metabolism/oxidative phosphorylation, (D) cellular stress). The row annotations
include the magnitude of difference between GC-sensitive and resistant samples (∆Ψ), type of the
splicing event (SE—exon skipping, A3SS—alternative 3’ splice site, A5SS—alternative 5’ splice site
and RI—intron retention) and whether the sequence directly affected by the splicing event encodes
a structural and/or functional protein domain (based on analysis performed using Maser package).
For the precise type of domains affected (annotated as in the Uniprot database), see Supplemental Data
S6 file.
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Figure A3. Correlation of rMATS-derived Percentage Spliced-In (Ψ) and PCR ratio of genes validated
by RT-PCR. (A) 13 genes validated for BCP-ALL dataset. (B) Nineteen genes validated for T-ALL
dataset. Genes are shown in decreasing order of the R2 coefficient. Adjusted p-values are reported.
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Figure A4. Dose–response curves obtained for CEM/R30dm after 72h incubation with 1 nM Plad-B 
combined with a dilution range of Dex. The expected effect was calculated (by multiplying the effects 
of both single agents alone) and plotted together with the dose–response curve to Dex alone and in 
combination with Plad-B. The arrows indicate points for which the observed response was greater 
than the expected response. Combination indexes (CI) calculated using Calcusyn are indicated above 
the arrows (mean CI = 0.276 ± 0.055). The panel depicts the mean of 3 independent experiments. 
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Table A1. The use of specific surface markers to define cell subpopulations in each sample. 
Sample Blast cell subpopulation T-cell subpopulation B-cell subpopulation 
T-ALL1 CD45-dim /CD3-/CD5+ CD45-high /CD3+ /CD5+ ND 
T-ALL2 CD45-dim /CD1a+ /CD5+ CD45-high /CD1a- /CD5+ ND 
T-ALL3 CD45-dim /CD34+ /CD5+ CD45-high /CD34- /CD5+ CD45-high /CD34- /CD19+ 
T-ALL4 CD45-dim /CD3-/CD5+ CD45-high /CD3+ /CD5+ CD45-high /CD19+ 
T-ALL5 CD45-dim /CD1a+ /CD3- CD45-high /CD1a- /CD3+ CD45-high /CD19+ 
T-ALL6 CD45-dim /CD34+ /CD5+ CD45-high /CD34-/CD5+ CD45-high /CD19+ 
ND—not determined 
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CD45-KO Beckman Coulter 
CD3-V450 BD Biosciences 
CD1a-APC BD Biosciences 
CD5-PE DAKO 
CD34-V450 BD Biosciences 
CD5-APC BD Biosciences 
CD3-PE BD Biosciences 
CD19-PC7 Beckman Coulter 
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Figure A4. Dose–response curves obtained for CEM/R30dm after 72h incubation with 1 nM Plad-B
combined with a dilution range of Dex. The expected effect was calculated (by multiplying the effects
of both single agents alone) and plotted together with the dose–response curve to Dex alone and in
combination with Plad-B. The arrows indicate points for which the observed response was greater than
the expected response. Combination indexes (CI) calculated using Calcusyn are indicated above the
arrows (mean CI = 0.276 ± 0.055). The panel depicts the mean of 3 independent experiments.
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Table A1. The use of specific surface markers to define cell subpopulations in each sample.
Sample Blast Cell Subpopulation T-Cell Subpopulation B-Cell Subpopulation
T-ALL1 CD45-dim /CD3-/CD5+ CD45-high /CD3+ /CD5+ ND
T-ALL2 CD45-dim /CD1a+ /CD5+ CD45-hi 1a- 5+ ND
T-ALL3 D45-dim /CD34+ /CD5+ CD45-high / 34- /CD5+ CD45-high /CD34- /CD19+
T-ALL4 CD45-di /CD3-/CD5+ CD45-high /C 3+ /CD5+ CD45-high /CD19+
T-ALL5 CD45-dim /CD1a+ /CD3- CD45-high /CD1a- /CD3+ CD45-high /CD19+
T-ALL6 CD45-dim /CD34+ /CD5+ CD45-high /CD34-/CD5+ CD45-high /CD19+
ND—not determined
Table A2. The list of fluor sce tly-lab led ant bod es used in this study.
Antibody Manufacturer
CD45-KO Beckman Coulter
CD3-V450 BD Biosciences
CD1a-APC BD Biosciences
CD5-PE DAKO
CD34-V450 BD Biosciences
CD5-APC BD Biosciences
CD3-PE BD Biosciences
CD19-PC7 Beckman Coulter
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Table A3. The list of primers used in this study.
Primer ID Sequence (5‘->3‘) Dataset
DYNC1I2_ex9_for AACAAATCTTGCACTCTGAGG BCP-ALL
DYNC1I2_ex11_rev GGCAGTGAAACACATACTCTGG BCP-ALL
UFC1_ex3_for GCTGGTATATCCATGACCTCCTG BCP-ALL
UFC1_ex6_rev GCCCTTCTGAATCAGATCAGGG BCP-ALL
PSMD11_ex10_for CTGATCCGAGTCATTGAGCC BCP-ALL
PSMD11_ex13_rev CTTTGTTGTAGAGGGAATCCACTAC BCP-ALL
SLC9A1_ex10_for TGCGGTCCTACAACAGACAC BCP-ALL
SLC9A1_ex12_rev GAAGACATCGTCGGTTCCTG BCP-ALL
SEC62_ex5_for AACTTGAGCCACATGATGATCAGG BCP-ALL
SEC62_ex8_rev TCCAGTTATGAGCCAAATGATGAG BCP-ALL
ARPC2_ex3-4_for TGCAGATTTCGATGGGGTCC BCP-ALL
ARPC2_ex6_rev CTTCAACATGCCAGCTTGATGCAC BCP-ALL
CUL2_ex3_for CATGTTCGGCATTTGCATAAG BCP-ALL
CUL2_ex6_rev CCTCCACATATCCAATGCTAG BCP-ALL
YWHAE_ex2_for GGATGTGGAGCTGACAGTTG BCP-ALL
YWHAE_ex4_rev GAGAGCAAGACCTAAGCGAATAG BCP-ALL
SOD1_ex1_for GTTTGCGTCGTAGTCTCCTG BCP-ALL
SOD1_ex3_rev CCGTGTTTTCTGGATAGAGG BCP-ALL
DNM2_ex6_for AAGGACATCCGTGCAGCACTG BCP-ALL
DNM2_ex9_rev GGCATAGCTGATCTCCCGTC BCP-ALL
SRSF5_ex7_rev TACTGTGCCTTTTGCTGCC BCP-ALL
SRSF7_ex3_for AAAGGTGATTTGTGGCTCCC BCP-ALL
SRSF7_ex4_rev TGCGTGAGCGAGAGTATCG BCP-ALL
TRA2A_ex1_for TCGACATGAGTGATGTGG BCP-ALL
TRA2A_ex2_rev ATGGGATTCAGAGTGTTTGG BCP-ALL
ANAPC5_ex14_for GCGGTTGTATTACAAGCTCAGAAC BCP-ALL
ANAPC5_ex15_rev AGCTCTGCCACGGACAGTAG BCP-ALL
TFIP11_ex2F GCCTGACTTCTAGCACTCCT T-ALL
TFIP11_ex5R TCAAAGTTCTCCCGCTCGTC T-ALL
HNRNPC_ex1F TCGGCGGCAGAGGAGAC T-ALL
HNRNPC_ex3R TGGAGCGAGGATCTGTCTTG T-ALL
CHUK_ex6F TCTGGGATATGCCAAAGATGTTGA T-ALL
CHUK_ex8R TGGCTACTAAACCGAACTTCTCC T-ALL
CDK4_ex1F TAGCTTGCGGCCTGTGTCTA T-ALL
CDK4_ex3R GGGGGTGCCTTGTCCAGATA T-ALL
CDK4_ex5R TGCAGAAGAACTTCGGGAGC T-ALL
HRAS_ex4F GGGTGAAGGACTCGGATGAC T-ALL
HRAS_ex6R TCAGGAGAGCACACACTTGC T-ALL
IKBKB_ex3F GAGCAGATTGCCATCAAGCAGTG T-ALL
IKBKB_ex6R TTTTCTGGCTTTAGATCCCGATGG T-ALL
HNRNPA1_ex6F GTCGAAGTGGTTCTGGAAACT T-ALL
HNRNPA1_ex9R ATAGCTACTGCTGCTGCTGG T-ALL
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Table A3. Cont.
Primer ID Sequence (5‘->3‘) Dataset
WDR33_ex10F TTTGCCAGTGGAGGGTCTGA T-ALL
WDR33_ex13R TGTTCTGGTATTCCCATTCCTGG T-ALL
THOC6_ex3F GTAAGAAGCCGGTGGTGACTT T-ALL
THOC6_ex5R TGTATGGAGGCTGACGACGC T-ALL
MX2_ex5F TGGAGATCACCTCCCCTGAG T-ALL
MX2_ex7R AGGTTCCGCACCACATTCAT T-ALL
BUD13_ex5F GATCTGTCACCTCCACGGAA T-ALL
BUD13_ex9R GTGCTGGACCACTGTAGCG T-ALL
SRSF3_ex3F CACTATGTGGCTGCCGTGTA T-ALL
SRSF3_ex5R CTCCGGCTGCGAGAGAAG T-ALL
U2AF1_ex2F GAGACAGGTGCTCTCGGTTG T-ALL
U2AF1_ex5R CTGCATCTCCACATCGCTCA T-ALL
U2AF1_ex7R TCACAGCCTTTTCCGCATCT T-ALL
SRPK2_ex13F AATAGGAGCGGGGTACAGCA T-ALL
SRPK2_ex16R TCAACCAAGGATGCCGAAGG T-ALL
PARN_ex2F GAGGAGGCCGACTTCTTCG T-ALL
PARN_ex6R AATCAAATCCCTGGCTTGCT T-ALL
APEX1_ex1F TCGGGTTAGGAGGAGCTAGG T-ALL
APEX1_ex2R CTTCGGCATTCCCGTTACGA T-ALL
SIRT6_ex6F CTGAGGGACACCATCCTAGAC T-ALL
SIRT6_ex7R GCGATGTACCCAGCGTGAT T-ALL
SMYD2_ex8F TCTCCTGTACCCAACGGAAG T-ALL
SMYD2_ex11R GGCCCATGTAGAGTCTCCCTA T-ALL
mTOR_ex7F GCAGTCAAATGCCTTGGTGG T-ALL
mTOR_ex9R CTCAGACCTCACAGCCACAG T-ALL
SRPK2_ex13F AATAGGAGCGGGGTACAGCA T-ALL
SRPK2_ex16R TCAACCAAGGATGCCGAAGG T-ALL
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